The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled. The study hypothesis is that measurement of the MBT will allow earlier detection of a decline in liver function in patients with cirrhosis who are awaiting liver transplantation.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
165
13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
Henry Ford Health System
Detroit, Michigan, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States
Hadassah Medical Center
Jerusalem, Israel, Israel
Mortality From Liver Failure
Patient dies of liver-related causes within 1 year of study entry
Time frame: 1 year
Liver Transplantation
Patient experiences complications of liver failure within 1 year of study entry and undergoes liver transplantation
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.